I Y K Iskandar1, D M Ashcroft1, R B Warren2, Z Z N Yiu2, K McElhone2, M Lunt3, J N W N Barker4, A D Burden5, A D Ormerod6, N J Reynolds7, C H Smith4, C E M Griffiths2. 1. Centre for Pharmacoepidemiology and Drug Safety, Manchester Pharmacy School, The University of Manchester, Manchester, U.K. 2. Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Barnes Building, Manchester, M6 8HD, U.K. 3. Arthritis Research U.K. Epidemiology Unit, The University of Manchester, Manchester, U.K. 4. St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, U.K. 5. Department of Dermatology, Western Infirmary, Glasgow, U.K. 6. Division of Applied Medicine, University of Aberdeen, Foresterhill, Aberdeen, U.K. 7. Dermatological Sciences, Institute of Cellular Medicine, Medical School, Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, U.K.
Abstract
BACKGROUND: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety of biologic and conventional systemic therapies used for adults with moderate-to-severe psoriasis in the U.K. and Republic of Ireland. OBJECTIVES: To describe the demographics, disease severity and comorbidities of patients with psoriasis on enrolment into BADBIR, and to highlight differences in those commencing biologics compared with those on conventional systemic therapies. METHODS: Baseline data were collected from 151 dermatology departments in the U.K. and Republic of Ireland. Descriptive analysis was conducted. RESULTS: As of August 2014, 8399 patients were registered with BADBIR; 5065 (60%) received biologics, of whom 52·8% received adalimumab, 24·6% etanercept, 18·7% ustekinumab and 3·9% infliximab. In the comparator cohort 44·1% received methotrexate, 23·1% ciclosporin, 18·0% acitretin and 7·6% fumaric acid esters. Overall 4897 (58%) were male. Patients on biologics had a higher mean ± SD age and disease duration than patients on conventional systemic therapies (46·3 ± 12·7 vs. 44·3 ± 14·3 years and 23·0 ± 12·6 vs. 19·0 ± 13·4 years, respectively; both P < 0·001). Mean body mass index, Psoriasis Area and Severity Index and Dermatology Life Quality Index scores for patients on biologics were higher than for those on conventional systemic therapies (31·0 ± 7·2 vs. 30·1 ± 7·3 kg m(-2) ; 16·4 ± 8·3 vs. 15·5 ± 7·9 and 17·4 ± 7·5 vs. 15·0 ± 7·1, respectively; all P < 0·001). In total 71% of all patients had comorbidities and 47% had more than one comorbidity. The most frequent comorbidities were obesity (42·1%), hypertension (25·7%), depression (22·1%) and psoriatic arthritis (17·1%). CONCLUSIONS: BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies.
BACKGROUND: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety of biologic and conventional systemic therapies used for adults with moderate-to-severe psoriasis in the U.K. and Republic of Ireland. OBJECTIVES: To describe the demographics, disease severity and comorbidities of patients with psoriasis on enrolment into BADBIR, and to highlight differences in those commencing biologics compared with those on conventional systemic therapies. METHODS: Baseline data were collected from 151 dermatology departments in the U.K. and Republic of Ireland. Descriptive analysis was conducted. RESULTS: As of August 2014, 8399 patients were registered with BADBIR; 5065 (60%) received biologics, of whom 52·8% received adalimumab, 24·6% etanercept, 18·7% ustekinumab and 3·9% infliximab. In the comparator cohort 44·1% received methotrexate, 23·1% ciclosporin, 18·0% acitretin and 7·6% fumaric acid esters. Overall 4897 (58%) were male. Patients on biologics had a higher mean ± SD age and disease duration than patients on conventional systemic therapies (46·3 ± 12·7 vs. 44·3 ± 14·3 years and 23·0 ± 12·6 vs. 19·0 ± 13·4 years, respectively; both P < 0·001). Mean body mass index, Psoriasis Area and Severity Index and Dermatology Life Quality Index scores for patients on biologics were higher than for those on conventional systemic therapies (31·0 ± 7·2 vs. 30·1 ± 7·3 kg m(-2) ; 16·4 ± 8·3 vs. 15·5 ± 7·9 and 17·4 ± 7·5 vs. 15·0 ± 7·1, respectively; all P < 0·001). In total 71% of all patients had comorbidities and 47% had more than one comorbidity. The most frequent comorbidities were obesity (42·1%), hypertension (25·7%), depression (22·1%) and psoriatic arthritis (17·1%). CONCLUSIONS: BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies.
Authors: Kayleigh J Mason; Jonathan N W N Barker; Catherine H Smith; Philip J Hampton; Mark Lunt; Kathleen McElhone; Richard B Warren; Zenas Z N Yiu; Christopher E M Griffiths; A David Burden Journal: JAMA Dermatol Date: 2018-05-01 Impact factor: 10.282
Authors: Nadeem Ahmed; James A Prior; Ying Chen; Richard Hayward; Christian D Mallen; Samantha L Hider Journal: Clin Rheumatol Date: 2016-08-02 Impact factor: 2.980
Authors: Zenas Z N Yiu; Lesley S Exton; Zarif Jabbar-Lopez; M Firouz Mohd Mustapa; Eleanor J Samarasekera; A David Burden; Ruth Murphy; Caroline M Owen; Richard Parslew; Vanessa Venning; Darren M Ashcroft; Christopher E M Griffiths; Catherine H Smith; Richard B Warren Journal: J Invest Dermatol Date: 2016-04-13 Impact factor: 8.551
Authors: J R Ingram; P N Woo; S L Chua; A D Ormerod; N Desai; A C Kai; K Hood; T Burton; F Kerdel; S E Garner; V Piguet Journal: Br J Dermatol Date: 2016-03-30 Impact factor: 9.302
Authors: Tom Hillary; Jolien Clijmans; Séverine Vermeire; Jo Lambert; Marjan Garmyn; Maya Imbrechts; Thomas Vanassche Journal: Ann Med Date: 2021-12 Impact factor: 4.709